Kumar Shivani, Choinski Krystina N, Tadros Rami O
Division of Vascular Surgery, Department of Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.
Division of Vascular Surgery, Department of Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai New York, New York.
Surg Technol Int. 2020 Nov 28;37:232-236.
Thoracic endovascular aortic repair (TEVAR) has become first-line therapy for a wide range of thoracic aortic pathologies including traumatic thoracic aortic injury, type B aortic dissection, intramural thoracic aortic hematoma, and penetrating aortic ulcers. This study aims to analyze the progress made of thoracic stent graft devices, review the current Food and Drug Administration (FDA)-approved devices, and discuss the future technological advances.
In this paper, we will review the history of TEVAR and the development of the first iteration of devices. We will discuss the four currently available TEVAR devices, the GORE® TAG® (W. L. Gore and Associates, Flagstaff, Arizona), Medtronic Navion™ (Medtronic plc, Santa Rosa, California), Bolton RELAY® (Terumo Aortic, Sunrise, Florida), and the Zenith® Alpha™ Thoracic and the Zenith® Dissection Stent Graft (Cook Medical, Bloomington, Indiana), and the features and applications of each. Finally, future advancements in TEVAR technology and grafts currently under trial will be reviewed.
The first generation of TEVAR grafts had several limitations including large delivery systems, the need for rapid pacing for accurate deployment, wind socking during deployment, and graft migration. The current available TEVAR grafts have novel features to address these prior pitfalls. The GORE® TAG® is initially deployed 50% with subsequent room for adjustment to increase accuracy; the Medtronic Navion™ and Bolton RELAY® are available in low-profile delivery systems; and the Cook Zenith® Alpha™ now has an open cell petticoat specific for use in dissections extending to the visceral abdominal aorta. The current generation of TEVAR devices have broadened the application of TEVAR and reduced the anatomic limitations previously encountered.
TEVAR has evolved to overcome technical challenges and offer expanded applicability to different types of thoracic aortic pathologies and enhanced accuracy of deployment.
胸主动脉腔内修复术(TEVAR)已成为多种胸主动脉病变的一线治疗方法,包括创伤性胸主动脉损伤、B型主动脉夹层、胸主动脉壁内血肿和穿透性主动脉溃疡。本研究旨在分析胸主动脉覆膜支架装置的进展,回顾美国食品药品监督管理局(FDA)目前批准的装置,并探讨未来的技术进步。
在本文中,我们将回顾TEVAR的历史以及第一代装置的发展。我们将讨论目前可用的四种TEVAR装置,即戈尔公司的TAG(W.L.戈尔公司,亚利桑那州弗拉格斯塔夫)、美敦力公司的Navion™(美敦力公司,加利福尼亚州圣罗莎)、博尔顿公司的RELAY®(泰尔茂主动脉公司,佛罗里达州日出)以及库克公司的Zenith® Alpha™胸主动脉覆膜支架和Zenith®夹层覆膜支架(库克医疗公司,印第安纳州布鲁明顿),并介绍每种装置的特点和应用。最后,将回顾TEVAR技术的未来进展以及目前正在试验的移植物。
第一代TEVAR移植物有几个局限性,包括输送系统庞大、需要快速起搏以精确展开、展开过程中出现“风袋”现象以及移植物移位。目前可用的TEVAR移植物具有新特性以解决这些先前的缺陷。戈尔公司的TAG最初展开50%,随后有调整空间以提高准确性;美敦力公司的Navion™和博尔顿公司的RELAY®采用低轮廓输送系统;库克公司的Zenith® Alpha™现在有一个开放细胞裙边,专门用于延伸至腹主动脉内脏段的夹层。当前一代的TEVAR装置拓宽了TEVAR的应用范围,并减少了先前遇到的解剖学限制。
TEVAR已经发展以克服技术挑战,并为不同类型的胸主动脉病变提供了更广泛的适用性,同时提高了展开的准确性。